Tested Applications
| Positive WB detected in | Jurkat cells |
| Positive IF/ICC detected in | A431 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:8000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
26326-1-AP targets C17orf75 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag23638 Product name: Recombinant human C17orf75 protein Source: e coli.-derived, PET30a Tag: 6*His Domain: 32-396 aa of BC035715 Sequence: PPSSSHYCLYSYRGSRLAQQRGDSEDGSPSGTNAETPSGDDFSLSLADTNLPSEVEPELRSFIAKRLSRGAVFEGLGNVASVELKIPGYRVGCYYCLFQNEKLLPETVTIDSERNPSEYVVCFLGGSEKGLELFRLELDKYIQGLKNNMNCEARGLESHIKSYLSSWFEDVVCPIQRVVLLFQEKLTFLLHAALSYTPVEVKESDEKTKRDINRFLSVASLQGLIHEGTMTSLCMAMTEEQHKSVVIDCSSSQPQFCNAGSNRFCEDWMQAFLNGAKGGNPFLFRQVLENFKLKAIQDTNNLKRFIRQAEMNHYALFKCYMFLKNCGSGDILLKIVKVEHEEMPEAKNVIAVLEEFMKEALDQSF Predict reactive species |
| Full Name | chromosome 17 open reading frame 75 |
| Observed Molecular Weight | 45 kDa |
| GenBank Accession Number | BC035715 |
| Gene Symbol | C17orf75 |
| Gene ID (NCBI) | 64149 |
| RRID | AB_3085857 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9HAS0 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
C17orf75, also known as Njmu-R1, mainly localizes to cytoplasmic vesicles and the trans-Golgi network (TGN). This protein is a component of the WDR11 complex (the WDR11-FAM91A1-C17orf75 trimer) and cooperates with TBC1D23 to promote the Golgi capture and tethering of AP-1-derived vesicles. In cancer research, C17orf75 is significantly overexpressed in various malignant tumors, including hepatocellular carcinoma, and is associated with poor prognosis and advanced clinicopathological features. Knockdown of C17orf75 inhibits tumor cell proliferation, migration, and invasion, induces G2 phase arrest, and suppresses epithelial-mesenchymal transition (EMT). This protein is an emerging molecule in studies of vesicular transport, tumor progression, and reproductive biology.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for C17orf75 antibody 26326-1-AP | Download protocol |
| WB protocol for C17orf75 antibody 26326-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The antibody 26326-1-AP (anti-C17orf75/Njmu-R1) has 1 total citation. It appears in Frontiers in Immunology, associated with research in hepatocellular carcinoma progression and pan-cancer analysis. The cited study validated C17orf75's role in promoting HCC using WB and IHC applications in human samples.
| Species | Application | Title |
|---|---|---|
Front Immunol C17orf75 (Njmu-R1) promotes hepatocellular carcinoma progression: a pan-cancer analysis and experimental validation
|
